Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Ehninger

Showing results (311-320 of 403) with videos related to

Pageof 41
Sort By:
The Lancet. Haematology|April 10, 2018
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trialMartin Wermke, Julia Eckoldt, Katharina S Götze, et al.
Haematologica|March 13, 2016
Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMTBipin N Savani, Myriam Labopin, Nicolaus Kröger, et al.
Blood|March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationJan M Middeke, Min Fang, Jan J Cornelissen, et al.
Frontiers in Oncology|April 7, 2022
Point Mutations in the <i>FLT3</i>-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant <i>KMT2A</i>-PTDSebastian Stasik, Michael Kramer, Sven Zukunft, et al.
Leukemia Research|December 24, 2010
Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survivalLara Tickenbrock, Hans-Ulrich Klein, Cristina Trento, et al.
Psycho-Oncology|September 5, 2012
Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter studyAngela Scherwath, Lena Schirmer, Margitta Kruse, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancerNicolaus Kröger, Markus Frick, Oleg Gluz, et al.
Bone Marrow Transplantation|October 8, 2020
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Helmuth Schmidt, Gero Hütter, et al.
Bone Marrow Transplantation|November 13, 2021
Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Helmuth Schmidt, Gero Hütter, et al.
Pageof 41

Showing results (311-320 of 403) with videos related to

Sort By:
Pageof 41
The Lancet. Haematology|April 10, 2018
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trialMartin Wermke, Julia Eckoldt, Katharina S Götze, et al.
Haematologica|March 13, 2016
Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMTBipin N Savani, Myriam Labopin, Nicolaus Kröger, et al.
Blood|March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationJan M Middeke, Min Fang, Jan J Cornelissen, et al.
Frontiers in Oncology|April 7, 2022
Point Mutations in the <i>FLT3</i>-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant <i>KMT2A</i>-PTDSebastian Stasik, Michael Kramer, Sven Zukunft, et al.
Leukemia Research|December 24, 2010
Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survivalLara Tickenbrock, Hans-Ulrich Klein, Cristina Trento, et al.
Psycho-Oncology|September 5, 2012
Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter studyAngela Scherwath, Lena Schirmer, Margitta Kruse, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancerNicolaus Kröger, Markus Frick, Oleg Gluz, et al.
Bone Marrow Transplantation|October 8, 2020
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Helmuth Schmidt, Gero Hütter, et al.
Bone Marrow Transplantation|November 13, 2021
Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Helmuth Schmidt, Gero Hütter, et al.
Pageof 41